J C Penney Company Inc NYSE: JCP, Zafgen Inc NASDAQ: ZFGN and Tasman Metals Ltd NYSEMKT: TAS are nearing market close with significant gains this Wednesday. Posting losses today are Eclipse Resources Corp NYSE: ECR, Enphase Energy Inc NASDAQ: ENPH and EXCO Resources Inc NYSE: XCO. Sign up for our free daily newsletter J C Penney Surges J C Penney Company Inc NYSE:JCP approached market close up +19.89% for the day thanks to a pleasant surprise on holiday sales. The struggling retailer has gained more than +18% over the past month. Billionaire hedge fund manager Larry Robbins has had a JCP stake since 2012, though by the third quarter of 2014, he had shaved his position down to just 196,000 shares. Zafgen Inc NASDAQ:ZFGN surged +16.88% on the heels of news of a successful mid-stage study on one of its obesity drugs. The biotech company was one of Farralon Capital's new third quarter acquisitions. Tasman Metals Ltd NYSEMKT:TAS rallied +13.09% today, a day after joining the U.S. Critical Metals Institute. A junior resource company, Tasman is a long-time George Soros holding. It has climbed +10.52% over the past month. Eclipse Resources Keeps Falling Eclipse Resources Corp NYSE:ECR continues to tumble in the wake of Deutsche Bank's target price cut, today falling -12.01%. ECR has fallen -59.78% over the past month - meaning losses for billionaire shareholders Leon Cooperman and Richard Chilton. Enphase Energy Inc NASDAQ:ENPH approached market close down -11.21%. Goldman Sachs began coverage of the stock today, issuing a sell rating and a price target of $12.94. Reports have also emerged of insider trading. Dan Loeb's Third Point Capital picked up a stake in ENPH during the second quarter of 2012 and has likely made a gain on the investment, given the stock's +80% climb since that time. EXCO Resources Inc NYSE:XCO dipped -10.52%, putting its five-day loss at -28.36%. The Wilbur Ross holding has fallen -36.14% over the past three months. J C Penney Rallies on Holiday Sales Surprise appeared first on ValueWalk. Sign up for our free newsletter -By iBillionaire
More from Stocks
Sarepta Craters After FDA Rejection of Muscular Dystrophy Drug
In its rejection of golodirsen, Sarepta's second treatment for Duchenne muscular dystrophy, the FDA cites concerns over infection risk "related to intravenous infusion ports and renal toxicity," the company said in a statement.
Watch These Huawei-Exposed Chips Stocks as White House Gives Extension to Huawei
Don't look at Nvidia and AMD. Look at these four instead.
Baidu Stock Continues Bull Run as Trade Optimism, Strong Earnings Spark Surge
The Chinese tech giant is charging hard to close August, adding hope for bulls betting on an inflection point.
Jim Cramer: Hail to Estee Lauder, the New England Patriots of Retail
Under CEO Fabrizio Freda, the cosmetics giant takes risks and then does the blocking and tackling needed to win in a challenging retail environment.